

Association of Life's Simple 7 with Atrial Fibrillation Burden (From the Atherosclerosis Risk in Communities Study)



Wendy Wang, MPH^{a,*}, Faye L. Norby, PhD^a, Mary R. Rooney, PhD^{a,b}, Michael Zhang, MD, PhD^c, Alejandra Gutierrez, MD^c, Parveen Garg, MD^d, Elsayed Z. Soliman, MD^e, Alvaro Alonso, MD, PhD^f, Samuel C. Dudley, Jr., MD, PhD^c, Pamela L. Lutsey, PhD^a, and Lin Y. Chen, MD^c

The American Heart Association's Life's Simple 7 (LS7) metric consists of 7 modifiable risk factors. Although a more favorable LS7 risk factor profile is associated with lower AF incidence, this relation is unknown in regard to AF burden. We assessed the prospective association of overall LS7 score and individual LS7 risk factors in midlife with AF burden in late-life in the Atherosclerosis Risk in Communities Study. LS7 components were assessed at Visit 3 (1993 to 1995) and a composite score ranging from 0 to 14 was calculated. A higher score indicates better cardiovascular health. AF burden was measured at Visit 6 (2016 to 2017) with a 2-week Zio XT Patch. AF burden, defined as the percent of time a participant was in AF, was categorized as none, intermittent (>0 to <100%), or continuous (100%). Weighted multinomial logistic regression was used. Of the 2,363 participants, 58% were female and 24% were black. Participants were aged 57 ± 5 years at Visit 3 and 79 ± 5 years at Visit 6. From the Zio XT Patch, 5% had continuous AF, 4% had intermittent AF, and 91% had none. After multivariable adjustment, each 1-point increase in LS7 score had 0.87 (95% CI: 0.79 to 0.95) higher odds of continuous AF than no AF. Individually, poor levels of physical activity, BMI, and fasting blood glucose were associated with greater AF burden. In conclusion, this population-based prospective cohort study reports that unfavorable cardiovascular health profile in midlife is associated with higher AF burden in late-life and future research to evaluate the effectiveness of optimizing physical activity, BMI, and fasting blood glucose in lowering AF burden is warranted. © 2020 Elsevier Inc. All rights reserved. (Am J Cardiol 2020;137:31–38)

Atrial fibrillation (AF) is a significant issue as its prevalence is expected to increase 3-fold in the next 3 decades.¹ A recent American Heart Association (AHA) Scientific Statement highlights the importance of considering the quantity of AF (i.e., AF burden) rather than just AF

presence or absence.² Higher AF burden is associated with adverse outcomes, but determinants of AF burden are not clearly defined.² The AHA's Life's Simple 7 (LS7) promotes ideal cardiovascular health and includes 7 modifiable health behaviors and factors (physical activity, total cholesterol, blood pressure, body mass index [BMI], fasting blood glucose, smoking, and diet).³ A more favorable LS7 risk factor profile is associated with lower AF incidence,⁴ but this has not yet been reported with respect to AF burden. The recent availability of an ECG recording device that records heart rhythm continuously for 2 weeks—Zio XT Patch (iRhythm Technologies, Inc, San Francisco, California)—facilitates AF burden measurement. We leveraged this technology to test the hypothesis that better LS7 score and individual LS7 risk factors in midlife are associated with lower AF burden in late life in participants in the Atherosclerosis Risk in Communities (ARIC) study.

^aDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota; ^bDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; ^cCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota; ^dDivision of Cardiology, Keck School of Medicine, University of Southern California, Los Angeles, California; ^eDepartment of Epidemiology, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina; and ^fDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. Manuscript received July 13, 2020; revised manuscript received and accepted September 23, 2020.

The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). The authors thank the staff and participants of the ARIC study for their important contributions. This work was also supported by grants from the National Heart Lung and Blood Institute [R01HL126637-01A1 (LYC), R01HL141288 (LYC), K24HL148521 (AA)] and the American Heart Association [16EIA26410001 (AA)].

*Corresponding author: Tel: +1 (612) 626-7755.
E-mail address: wang5694@umn.edu (W. Wang).

Methods

The ARIC Study⁵ is a prospective, community-based cohort, which began in 1987 to 1989. At baseline, the 15,792 participants were aged 45 to 64 years and recruited from 4 US communities (Forsyth County, North Carolina; Jackson, Mississippi; Washington County, Maryland; selected suburbs of Minneapolis, Minnesota). Several additional clinical exams have since taken place. Visit 3 (1993 to 1995) served as the baseline for this analysis. At Visit 6

(2016 to 2017), 4,003 participants aged 75 to 94 years attended and were invited to wear a Zio XT Patch. The prescribed wear time was 14 days. Exclusion criteria included history of cardiac electronic device implantation or skin allergic reaction to adhesive tape. After the recording period, participants mailed the device to iRhythm Technologies Inc., where recorded ECG data were processed using a proprietary algorithm and a report was generated. Of the 2,650 participants who wore the device, 34 (1.3%) were lost or returned without data resulting in 2,616 devices with analyzable data. Exclusion criteria for this analysis included races other than black or white and non-whites in the MN and MD centers (due to small numbers), wearing the Zio XT Patch <48 hours or missing LS7 covariates, leaving an analytic sample of 2,363 (Figure 1). Institutional review boards at each center approved the study.

LS7 components were assessed at midlife at Visit 3. Physical activity was measured using the modified Baecke questionnaire⁶ and responses were converted to minutes per week of moderate or vigorous exercise.⁷ Sitting blood pressure were measured 3 times and the final 2 measures were

averaged. BMI was calculated from weight and height. Enzymatic procedures were used to assess total blood cholesterol concentration.⁸ Fasting blood glucose was measured by the modified hexokinase/glucose-6-phosphate dehydrogenase method. Participants self-reported cigarette smoking status as current, former, or never. Former smokers were categorized based on smoking quit date (>12 vs ≤12 months). Diet was measured using a 66-item food frequency questionnaire.⁹ The healthy diet score was calculated by meeting nutritional guidelines in 5 areas: fruits and vegetables, fish, sodium, sugar-sweetened beverages, and whole grains.

Each LS7 component was categorized as poor (0 points), intermediate (1 point), or ideal (2 points) based on the AHA's LS7 criteria,³ as has been done previously in ARIC.¹⁰ Briefly, ideal levels were: ≥150 min/week of physical activity, total cholesterol <200 mg/dl, blood pressure <120/80 mm Hg, BMI <25 kg/m², fasting blood glucose <100 mg/dl, nonsmokers or quit >12 months ago, and a healthy diet score (≥4 components). **Supplemental Table 1** shows the intermediate and poor levels for each




Figure 1. Study sample inclusion flowchart.

component, respectively. Participants taking medications to achieve target levels for cholesterol, blood pressure, or blood glucose were classified as intermediate for each respective health factor. An overall LS7 composite score ranging from 0 to 14 was calculated. A higher score indicates better health. The composite score was categorized as inadequate (0 to 4), average (5 to 9), or optimum (10 to 14) cardiovascular health.¹⁰

AF burden was defined as the percent of time a participant was in AF, as computed from the Zio XT Patch data using iRhythm's proprietary algorithm. AF burden was categorized into no AF (0%), intermittent AF (>0 to <100%), or continuous AF (100%).

Other self-reported covariates measured at Visit 3 included age, gender, race (black, white), ARIC field center, and drinking status (current, never). Educational attainment was obtained from Visit 1. Coronary heart disease (CHD), stroke, and heart failure (HF) events were identified through Visit 6 and used as mediators in this analysis. Beta-blocker and calcium-channel blocker medication use was collected at Visit 6. Technicians recorded medication use through review of medication bottles. HF was identified by the Gothenburg criteria (Visit 1 only), self-report of HF medication use within the past 2 weeks, or presence of ICD codes for HF in any hospitalization or during follow-up before Visit 6.¹¹ CHD was defined by self-reported physician diagnosis at visit 1, history of myocardial infarction on ECG, or adjudicated cases following visit 1.^{11,12} Stroke was defined as the self-reported history of a physician diagnosis of a stroke before visit 1; following visit 1, stroke was adjudicated from diagnosis codes indicative of cerebrovascular disease using criteria adapted from the National Survey of Stroke.¹³

Baseline characteristics of participants who wore the Zio XT Patch were described as mean (standard deviation [SD]) for continuous variables and percentages for categorical variables. Multinomial logistic regression was used to compute the odds ratios (OR) and 95% confidence intervals

(CI) for the association of LS7 composite score with AF burden. ORs for AF burden were also calculated for each LS7 risk factor individually and per 1-unit higher LS7 score. Multivariable models were used: Model 1 adjusted for age, gender, race/center (5 levels); Model 2 additionally adjusted for education and drinking status; Model 3 further adjusted for CHD, stroke, HF, beta-blockers, and calcium-channel blockers (all collected through Visit 6). To account for potential survival bias, we used inverse probability weighting to account for attrition due to death, failure to attend Visit 6, or not wearing the Zio XT Patch.¹⁴ The ideal overall health category or optimum risk factor level was used as the reference group. Analyses were conducted using SAS software (version 9.4; SAS Institute Inc., Cary, North Carolina).

Results

Visit 3 participant characteristics, stratified by Visit 6 AF burden categories, are presented in **Table 1**. The 2,363 participants included in this analysis were on average (SD), 56.7 (4.6) years at Visit 3 (baseline) and 79.2 (4.7) year at Visit 6; 58% were female, whereas 24% were black. Mean LS7 score at Visit 3 was 8.6 (2.1) and mean Zio XT Patch wear time at Visit 6 was 12.6 (2.6) days. Visit 6 took place an average (SD) of 22.5 (0.9) years after Visit 3. Among those who wore the Zio XT Patch, 117 (5%) had continuous, 83 (4%) had intermittent, and 2,163 (91%) had no AF. Those with continuous AF at Visit 6 were at Visit 3 older, more likely to be male, and had more prevalent CHD than those with intermittent or no AF at Visit 6.

Overall, 36% of participants were in the ideal LS7 composite category, 3% in the intermediate category, and 61% in the poor category. The most common ideal LS7 factors were fasting blood glucose (58%) and smoking status (87%), whereas ideal diet was the least common ideal LS7 factor (2%). The distribution of the LS7 composite and

Table 1

Midlife (1993–1995) characteristics of study participants by late life (2016–2017) atrial fibrillation burden categories: The Atherosclerosis Risk in Communities Study*

Variable	Atrial Fibrillation Burden in 2016–17		
	None (n = 2,163)	Intermittent (n = 83)	Continuous (n = 117)
Age (years)	56.6 (5)	57.5 (4)	59.3 (5)
Men	41%	41%	60%
Black	24%	13%	14%
Education, < high school degree	12%	6%	13%
Current alcohol drinkers	57%	65%	58%
Body mass index (kg/m ²)	27.8 (5)	28.5 (6)	29.7 (6)
Systolic blood pressure (mm Hg)	118.8 (16)	119.0 (18)	122.3 (16)
Diastolic blood pressure (mm Hg)	71.8 (10)	70.7 (10)	71.8 (9)
Total cholesterol (mg/dl)	204.3 (36)	206.6 (41)	199.7 (36)
Fasting blood glucose (mg/dl)	102.3 (26)	99.8 (20)	108.6 (34)
Coronary heart disease	3%	4%	6%
Heart failure	1%	0%	1%
Stroke	1%	0%	0%
Beta-blockers	11%	18%	12%
Calcium-channel blockers	10%	18%	16%

* Data are expressed as mean (SD) or %.

Table 2

Life's Simple 7 (LS7) distribution by atrial fibrillation burden categories: The Atherosclerosis Risk in Communities Study, 1993–1995

Variable	Atrial Fibrillation Burden in 2016–2017		
	None (n = 2,163)	Intermittent (n = 83)	Continuous (n = 117)
LS7 health categories			
Inadequate	58 (3%)	4 (5%)	4 (3%)
Average	1,323 (61%)	44 (53%)	82 (70%)
Optimum	782 (36%)	35 (42%)	31 (27%)
Individual LS7 components			
Physical activity			
Poor	718 (33%)	21 (25%)	46 (39%)
Intermediate	524 (24%)	28 (34%)	26 (22%)
Ideal	921 (43%)	34 (41%)	45 (39%)
Total cholesterol (mg/dl)			
Poor (> 240)	320 (15%)	18 (22%)	13 (11%)
Intermediate (200–239 or treated to <200)	861 (40%)	27 (32%)	46 (39%)
Ideal (<200, without medication)	982 (45%)	38 (46%)	58 (50%)
Blood pressure (mm Hg)			
Poor (SBP >140 or DBP >90)	248 (12%)	11 (13%)	15 (13%)
Intermediate (SBP 120–139 or DBP 80–89 or treated to <120/<80)	871 (40%)	33 (40%)	57 (49%)
Ideal (<120/<80, without medication)	1,044 (48%)	39 (47%)	45 (38%)
Body mass index (kg/m ²)			
Poor (>30)	589 (27%)	33 (40%)	43 (37%)
Intermediate (25 - <30)	935 (43%)	24 (29%)	47 (40%)
Ideal (<25)	639 (30%)	26 (31%)	27 (23%)
Fasting blood glucose (mg/dl)			
Poor (>126)	131 (6%)	6 (7%)	10 (9%)
Intermediate (100–125 or treated to <100)	763 (35%)	19 (23%)	52 (44%)
Ideal (<100, without medication)	1,269 (59%)	58 (70%)	55 (47%)
Smoking status			
Poor	262 (12%)	11 (13%)	7 (6%)
Intermediate	26 (1%)	2 (3%)	5 (4%)
Ideal	1,875 (87%)	70 (84%)	105 (90%)
Diet			
Poor	903 (42%)	35 (42%)	51 (43%)
Intermediate	1,211 (56%)	43 (52%)	65 (56%)
Ideal	49 (2%)	5 (6%)	1 (1%)

individual factors, stratified by the AF burden categories, is shown in [Table 2](#).

The ORs (95% CIs) of Visit 3 LS7 and Visit 6 AF burden are shown in [Table 3](#). We did not observe any statistically significant associations between LS7 categories and intermittent AF versus no AF. However, compared with optimal LS7 category, those with inadequate and average LS7 had 3.95 and 1.82 times the odds of continuous AF than no AF. Similarly, for each 1-point higher LS7 score, the odds of continuous AF in Model 2 was 0.87 relative to no AF, indicating that those with more favorable LS7 score in mid-life had lower odds of continuous AF than no AF in late-life. These associations were attenuated with further adjustment for potential mediators (cardiovascular events and medications). There was no association between any of the LS7 score categories when comparing the odds of continuous versus intermittent AF.

To determine the association between individual LS7 components and AF burden, separate models were analyzed. [Table 4](#) shows the odds of AF burden for each LS7 factor. No associations were noted when assessing the relation between any of the individual LS7 components and intermittent AF compared with no AF. Poor BMI was associated with 2.36-fold increased odds of continuous AF as

compared with ideal BMI in Model 2. Those with poor levels of physical activity had 1.64 times higher odds of continuous AF than no AF. Both poor and intermediate levels of fasting blood glucose had 2.28 and 1.71 times the odds of continuous AF than no AF, respectively. Further adjustment for potential mediators (cardiovascular events and medications) attenuated these associations. There were no consistent significant associations between individual LS7 components and continuous AF versus intermittent AF noted.

Discussion

In this population-based prospective cohort study, we investigated the relationship between modifiable lifestyle behaviors and factors in midlife and AF burden in late life. Our study, which followed a large cohort of individuals from midlife for over 20 years, advances the field on several fronts. Our principal findings are: (1) a more favorable LS7 score was associated with lower odds of continuous versus no AF; and (2) individually, poor physical activity, BMI, and fasting blood glucose were associated with higher odds of continuous versus no AF. Collectively, our findings suggest that having an optimal lifestyle in middle age may

Table 3
Weighted* odds ratios (95% confidence intervals) of atrial fibrillation burden with overall Life's Simple 7 (LS7) score: The Atherosclerosis Risk in Communities Study, 1993–2017

LS7 health categories	Atrial Fibrillation Burden								
	Intermittent vs. None			Continuous vs. None			Continuous vs. Intermittent		
	Model 1	Model 2	Model 3	Model 1	Model 2	Model 3	Model 1	Model 2	Model 3
Inadequate	2.42 (0.92–6.37)	2.38 (0.90–6.33)	2.18 (0.81–5.85)	3.41 (1.38–8.41)	3.95 (1.58–9.88)	2.07 (0.79–5.39)	1.41 (0.40–5.01)	1.66 (0.46–6.01)	0.95 (0.25–3.59)
Average	0.92 (0.56–1.50)	0.89 (0.54–1.46)	0.83 (0.50–1.37)	1.72 (1.08–2.75)	1.82 (1.14–2.92)	1.32 (0.81–2.16)	1.87 (0.97–3.62)	2.04 (1.05–3.98)	1.60 (0.80–3.18)
Optimum	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)
Per 1-point increase	0.92 (0.83–1.02)	0.92 (0.83–1.02)	0.96 (0.84–1.10)	0.89 (0.81–0.97)	0.87 (0.79–0.95)	0.94 (0.82–1.08)	0.96 (0.84–1.09)	0.94 (0.82–1.07)	1.02 (0.88–1.17)

Model 1: adjusted for age, sex, race/center.

Model 2: adjusted for model 1 plus education and drinking status.

Model 3: adjusted for model 2 plus coronary heart disease, stroke, heart failure, beta-blockers, and calcium-channel blockers (all measured through Visit 6).

* Inverse-probability weighting was used.

result in lower AF burden in older age. This expands upon previous work which has shown a healthful lifestyle to be associated with lower AF incidence.⁴

Increased cardiorespiratory fitness is associated with a reduced risk of incident AF.¹⁵ Patients with permanent AF who participated in an exercise program reported an improvement in quality of life and reduction in AF-related symptoms.¹⁶ However, the relation between physical activity and AF burden have produced mixed results. A Norwegian clinical trial showed that 12 weeks of aerobic interval training reduces AF burden in AF patients, indicating an increase in physical activity reduces AF burden,¹⁷ similar to our results. On the other hand, a clinical trial in Copenhagen found that high intensity exercise was not superior to low intensity exercise in decreasing AF burden in AF patients.¹⁸ Though our study only showed a significant increase in odds of intermittent AF, the measures of association comparing the odds of continuous AF and no AF were in the hypothesized direction for physical activity.

Obesity has been found to be the most prominent modifiable risk factor that influences lifetime AF risk.¹⁹ The LEGACY study reported that in patients referred for symptomatic AF treatment, weight loss results in a reduction of AF burden.²⁰ Similarly, a clinical trial found that overweight and obese patients with symptomatic AF who participated in a structured weight management program had fewer AF episodes seen on 7-day Holter monitors and reduced AF symptom burden.²¹ An increase in cardiorespiratory fitness is associated with a decreased risk of incident AF, with the association strongest in obese patients,¹⁵ whereas a dose-dependent reduction in AF burden was noted in obese patients.²² These previous findings, in addition to our results, suggest a combination of exercise training and weight loss may further reduce AF burden.

Diabetes is an established risk factor for AF.²³ A previous ARIC study found that patients with diabetes have a 30% greater risk of incident AF than those without diabetes,²⁴ similar to results from a meta-analysis.²³ AF risk is further increased in those with longer diabetes duration and worse glycemic control,²⁵ with fasting blood glucose independently associated with a higher risk of AF in those with diabetes.²⁴ This association was not seen in those without diabetes, suggesting that AF may be related to cumulative exposure to hyperglycemia.²⁴ Better glycemic control before ablation in patients with diabetes is associated with a reduction in AF recurrence after AF ablation,²⁶ highlighting the importance of screening for diabetes early. To our knowledge, our study is the first to show that compared with intermediate and poor levels, ideal fasting blood glucose in midlife is associated with lower AF burden in older age. Achieving good glycemic control may be an effective strategy to lower AF burden in late life.

Studies assessing the effect of a combination of risk factors on AF burden are scarce. The ARREST-AF study found that patients who participated in a risk factor management program had a decrease in AF burden after AF ablation.²⁷ Many risk factors in this program are included in LS7, suggesting that overall healthy cardiovascular behaviors may lower AF burden. This was supported by our study, which showed that a more favorable LS7 score was associated with lower odds of continuous AF versus no AF.

Table 4

Weighted* odds ratios (95% confidence intervals) of atrial fibrillation burden with individual Life's Simple 7 components: The Atherosclerosis Risk in Communities Study, 1993–2017

	Atrial Fibrillation Burden								
	Intermittent vs. None			Continuous vs. None			Continuous vs. Intermittent		
	Model 1	Model 2	Model 3	Model 1	Model 2	Model 3	Model 1	Model 2	Model 3
Physical activity									
Poor	1.10 (0.62–1.94)	1.09 (0.61–1.95)	1.08 (0.60–1.92)	1.51 (0.99–2.32)	1.64 (1.06–2.56)	1.56 (0.98–2.47)	1.38 (0.69–2.77)	1.51 (0.74–3.07)	1.45 (0.70–2.99)
Intermediate	1.85 (1.09–3.15)	1.83 (1.08–3.12)	1.84 (1.08–3.13)	1.09 (0.66–1.82)	1.12 (0.67–1.86)	1.08 (0.63–1.82)	0.59 (0.29–1.21)	0.61 (0.30–1.25)	0.59 (0.28–1.22)
Ideal	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)
Total cholesterol									
Poor	1.59 (0.89–2.86)	1.58 (0.88–2.85)	1.53 (0.85–2.76)	0.85 (0.47–1.53)	0.88 (0.49–1.57)	0.71 (0.39–1.30)	0.54 (0.24–1.20)	0.55 (0.25–1.24)	0.46 (0.20–1.06)
Intermediate	0.93 (0.56–1.55)	0.92 (0.55–1.54)	0.89 (0.53–1.49)	0.99 (0.67–1.49)	1.01 (0.67–1.51)	0.89 (0.59–1.36)	1.07 (0.57–2.02)	1.09 (0.58–2.06)	1.00 (0.52–1.92)
Ideal	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)
Blood pressure									
Poor	1.22 (0.60–2.47)	1.20 (0.59–2.44)	0.98 (0.46–2.07)	1.22 (0.67–2.23)	1.29 (0.70–2.36)	0.56 (0.29–1.09)	1.00 (0.41–2.48)	1.08 (0.43–2.67)	0.57 (0.21–1.52)
Intermediate	1.18 (0.72–1.92)	1.15 (0.70–1.89)	1.00 (0.60–1.68)	1.61 (1.05–2.45)	1.65 (1.08–2.52)	1.14 (0.72–1.80)	1.37 (0.72–2.57)	1.43 (0.76–2.70)	1.13 (0.58–2.22)
Ideal	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)
Body mass index									
Poor	1.67 (0.96–2.90)	1.64 (0.94–2.86)	1.61 (0.92–2.81)	2.30 (1.37–3.84)	2.36 (1.41–3.97)	1.83 (1.08–3.13)	1.38 (0.66–2.87)	1.44 (0.69–3.01)	1.14 (0.54–2.42)
Intermediate	0.60 (0.33–1.10)	0.60 (0.33–1.10)	0.59 (0.32–1.07)	1.03 (0.62–1.73)	1.04 (0.62–1.73)	0.93 (0.55–1.57)	1.71 (0.79–3.72)	1.74 (0.80–3.78)	1.59 (0.72–3.49)
Ideal	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)
Fasting blood glucose									
Poor	1.12 (0.52–2.39)	1.19 (0.56–2.56)	1.13 (0.53–2.44)	2.26 (1.25–4.11)	2.28 (1.26–4.16)	1.70 (0.91–3.19)	2.02 (0.80–5.15)	1.91 (0.75–4.90)	1.50 (0.58–3.93)
Intermediate	0.55 (0.32–0.95)	0.54 (0.31–0.92)	0.53 (0.31–0.91)	1.64 (1.09–2.47)	1.71 (1.13–2.58)	1.48 (0.97–2.27)	2.97 (1.54–5.76)	3.20 (1.65–6.22)	2.80 (1.43–5.49)
Ideal	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)
Smoking status									
Poor	1.27 (0.73–2.23)	1.28 (0.73–2.26)	1.28 (0.73–2.26)	0.63 (0.35–1.15)	0.65 (0.36–1.18)	0.57 (0.30–1.06)	0.50 (0.22–1.10)	0.51 (0.23–1.13)	0.44 (0.19–1.02)
Intermediate	2.19 (0.49–9.77)	2.23 (0.50–9.99)	2.27 (0.50–10.3)	4.55 (1.75–11.8)	4.60 (1.76–12.1)	3.86 (1.39–10.7)	2.09 (0.39–10.9)	2.07 (0.39–11.0)	1.70 (0.31–9.45)
Ideal	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)
Diet									
Poor	0.42 (0.15–1.20)	0.46 (0.16–1.33)	0.49 (0.17–1.43)	1.80 (0.26–12.4)	1.74 (0.25–12.0)	2.21 (0.30–16.0)	4.31 (0.50–37.2)	3.76 (0.43–32.7)	4.47 (0.50–40.4)
Intermediate	0.36 (0.13–1.01)	0.40 (0.14–1.13)	0.41 (0.14–1.17)	1.94 (0.28–13.3)	1.85 (0.27–12.7)	2.18 (0.30–15.6)	5.43 (0.64–46.2)	4.62 (0.54–39.6)	5.31 (0.60–47.2)
Ideal	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)	1 (ref)

Model 1: adjusted for age, sex, race/center.

Model 2: adjusted for model 1 plus education and drinking status.

Model 3: adjusted for model 2 plus coronary heart disease, stroke, heart failure, beta-blockers, and calcium-channel blockers (measured at Visit 6).

* Inverse probability weighting was used.

In addition, evidence is accumulating to indicate that structured risk factor management is not only clinically effective, but also more cost-effective than usual care.²⁸ Our findings that physical activity, BMI, and fasting blood glucose are the LS7 factors most consistently associated with lower AF burden form the basis to test the efficacy and cost-effectiveness of a structured program encompassing these 3 factors in lowering AF burden. Interestingly, no consistent association between elevated blood pressure (an established AF risk factor)²⁹ and AF burden was seen. As few studies have assessed the relationship between blood pressure and AF burden,³⁰ more research to confirm this finding is needed.

Strengths of this study include the prospective design, long follow-up, representation of black and white men and women, and high percent analyzable time achieved with the Zio[®] XT Patch. However, limitations exist. First, some LS7 and AF burden categories were small (e.g., inadequate LS7, intermittent or continuous AF), resulting in imprecise effect estimates. Second, although we utilized inverse probability weighting, selection bias in regard to visit non-attendance or not agreeing to wear the Zio XT Patch may have occurred. Third, only 83 participants had intermittent AF (AF burden <100%), which did not provide the spread of data and power to adequately evaluate percent of time spent in AF. Fourth, although it would be of interest to evaluate the trajectories of LS7 and its components over time, it is not possible to calculate a complete LS7 score at each visit given that some variables (e.g., diet, physical activity) were not assessed at all visits. Finally, similar to other observational studies, residual confounding cannot be excluded.

In conclusion, this population-based prospective cohort study indicates that lower levels of overall cardiovascular health in midlife (as defined by LS7) is associated with higher AF burden in older age. Individually, poor levels of physical activity, BMI, and fasting blood glucose were each associated with higher AF burden. Selective targeting of these lifestyle factors in midlife may help to lower AF burden in older age. Future research to evaluate the effectiveness of optimizing these 3 factors in lowering AF burden is warranted.

Authors contribution

Wendy Wang: Conceptualization, Methodology, Formal analysis, Writing – original draft, Visualization; **Faye L. Norby:** Methodology, Writing – review & editing; **Mary R. Rooney:** Writing – review & editing; **Michael Zhang:** Writing – review & editing; **Alejandra Gutierrez:** Writing – review & editing; **Parveen Garg:** Writing – review & editing; **Elsayed Z. Soliman:** Writing – review & editing; **Alvaro Alonso:** Writing – review & editing; **Samuel C. Dudley, Jr.:** Writing – review & editing; **Pamela L. Lutsey:** Writing – review & editing; **Lin Y. Chen:** Conceptualization, Writing – review & editing, Supervision, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relations that could have appeared to influence the work reported in this report.

Supplementary materials

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.amjcard.2020.09.033>.

- Morin DP, Bernard ML, Madias C, Rogers PA, Thihalolipavan S, Estes NA. The state of the art: atrial fibrillation epidemiology, prevention, and treatment. *Mayo Clin Proc* 2016;91:1778–1810.
- Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, Noseworthy PA, Perez MV, Turakhia MP, Cardiology AHACoC, Nursing CoCaS, Research CoQoCaO, Council aS. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. *Circulation* 2018;137:e623–e644.
- Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD, Committee AHA/STPFA. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation* 2010;121:586–613.
- Garg PK, O'Neal WT, Chen LY, Loehr LR, Sotoodehnia N, Soliman EZ, Alonso A. American Heart Association's life simple 7 and risk of atrial fibrillation in a population without known cardiovascular disease: The ARIC (Atherosclerosis Risk in Communities) Study. *J Am Heart Assoc* 2018;7:e008424.
- The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. *Am J Epidemiol* 1989;129:687–702.
- Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36:936–942.
- Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, Bassett DR, Schmitz KH, Emplaincourt PO, Jacobs DR, Leon AS. Compendium of physical activities: an update of activity codes and MET intensities. *Med Sci Sports Exerc* 2000;32:S498–S504.
- Siedel J, Hägele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. *Clin Chem* 1983;29:1075–1080.
- Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE. Reproducibility and validity of a semi-quantitative food frequency questionnaire. *Am J Epidemiol* 1985;122:51–65.
- Folsom AR, Shah AM, Lutsey PL, Roetker NS, Alonso A, Avery CL, Miedema MD, Konety S, Chang PP, Solomon SD. American Heart Association's Life's Simple 7: avoiding heart failure and preserving cardiac structure and function. *Am J Med* 2015;128:970–976. e972.
- Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). *Am J Cardiol* 2008;101:1016–1022.
- Rosamond WD, Chambless LE, Heiss G, Mosley TH, Coresh J, Whitel E, Wagenknecht L, Ni H, Folsom AR. Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987–2008. *Circulation* 2012;125:1848–1857.
- Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. *Stroke; a journal of cerebral circulation* 1999;30:736–743.
- Weuve J, Tchetgen Tchetgen EJ, Glymour MM, Beck TL, Aggarwal NT, Wilson RS, Evans DA, Mendes de Leon CF. Accounting for bias due to selective attrition: the example of smoking and cognitive decline. *Epidemiology* 2012;23:119–128.
- Qureshi WT, Alirhayim Z, Blaha MJ, Juraschek SP, Keteyian SJ, Brawner CA, Al-Mallah MH. Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing (FIT) Project. *Circulation* 2015;131:1827–1834.

16. Osbak PS, Mourier M, Kjaer A, Henriksen JH, Kofoed KF, Jensen GB. A randomized study of the effects of exercise training on patients with atrial fibrillation. *Am Heart J* 2011;162:1080–1087.
17. Malmo V, Nes BM, Amundsen BH, Tjonna AE, Stoylen A, Rossvoll O, Wisloff U, Loennechen JP. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. *Circulation* 2016;133:466–473.
18. Skielboe AK, Bandholm TQ, Hakmann S, Mourier M, Kallemose T, Diken U. Cardiovascular exercise and burden of arrhythmia in patients with atrial fibrillation - A randomized controlled trial. *PLoS One* 2017;12:e0170060.
19. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, McManus DD, Ko D, Weng LC, Lunetta KL, Frost L, Benjamin EJ, Trinquart L. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. *BMJ* 2018;361:k1453.
20. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). *J Am Coll Cardiol* 2015;65:2159–2169.
21. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA* 2013;310:2050–2060.
22. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. *J Am Coll Cardiol* 2015;66:985–996.
23. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol* 2011;108:56–62.
24. Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR, Soliman EZ, Pankow JS, Selvin E. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. *Heart* 2012;98:133–138.
25. Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. *J Gen Intern Med* 2010;25:853–858.
26. Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, Baranowski B, Hussein A, Saliba W, Wazni O. Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation. *JACC Clin Electrophysiol* 2019;5:897–903.
27. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *J Am Coll Cardiol* 2014;64:2222–2231.
28. Pathak RK, Evans M, Middeldorp ME, Mahajan R, Mehta AB, Meredith M, Twomey D, Wong CX, Hendriks JML, Abhayaratna WP, Kalman JM, Lau DH, Sanders P. Cost-effectiveness and clinical effectiveness of the risk factor management clinic in atrial fibrillation: The CENT Study. *JACC Clin Electrophysiol* 2017;3:436–447.
29. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclellan R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2011;123:1501–1508.
30. Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Raisakis K, Kaoukis A, Karageorgiou S, Bouras G, Katsivas A, Pyrgakis V, Stefanadis C. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. *Am J Cardiol* 2013;112:684–687.